Organon price to free cash flow OGN

Market value divided by free cash flow over the last twelve months, since 2022.

Today, Oct 23, 2026: 6.4×
5-year median: 6.5×
Against its 5-year history: 47th; percentile: 0 is its lowest day, 100 its highest
5-year range: 2.3× to 18.3×
Peer median: 32.9×

Organon's price to free cash flow is 6.4× as of Oct 23, 2026.

That is below its 5-year median of 6.5×, close to the middle of its last 5 years.

Over that time it ranged from 2.3× in Dec 2025 to 18.3× in Jan 2023.

The median for 10 large drugmakers of a similar size is 32.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	6.4×	2.4×	6.4×
2025	2.4×	2.3×	5.5×
2024	5.2×	5.0×	11.2×
2023	8.5×	6.5×	18.3×
2022	15.9×	4.2×	15.9×

Against its peers

Companies in Drug Manufacturers - General nearest Organon's size, closest first, today.

Company	Price to free cash flow
OGNOrganon	6.4×
LQDALiquidia	25.3×
ARQTArcutis Biotherapeutics	100×
INDVIndivior Pharmaceuticals	n/m
NRIXNurix Therapeutics	7.5×
PBHPrestige Consumer Healthcare	9.6×
KNSAKiniksa Pharmaceuticals International	32.7×
LGNDLigand Pharmaceuticals	46.0×
HRMYHarmony Biosciences	n/m
AMRXAmneal Pharmaceuticals	50.9×
ALKSAlkermes plc.	33.0×
Peer median	32.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Organon

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.